The purpose of this study is to measure the safety and decrease in daytime sleepiness in subjects with Idiopathic Hypersomnia when taking ALKS 2680 tablets compared with placebo tablets
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
96
Change in Epworth Sleepiness Scale (ESS) from baseline to Week 8 by dose level
Time frame: Up to 8 weeks
Change in Idiopathic Hypersomnia Severity Scale (IHSS) from baseline to Week 8 by dose level
Time frame: Up to 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alkermes Investigator Site
Cullman, Alabama, United States
RECRUITINGAlkermes Investigator Site
Phoenix, Arizona, United States
RECRUITINGAlkermes Investigator Site
Little Rock, Arkansas, United States
RECRUITINGAlkermes Investigator Site
Los Angeles, California, United States
RECRUITINGAlkermes Investigator Site
Redwood City, California, United States
RECRUITINGAlkermes Investigator Site
San Francisco, California, United States
RECRUITINGAlkermes Investigator Site
Colorado Springs, Colorado, United States
RECRUITINGAlkermes Investigator Site
Brandon, Florida, United States
RECRUITINGAlkermes Investigator Site
Miami, Florida, United States
RECRUITINGAlkermes Investigator Site
Winter Park, Florida, United States
RECRUITING...and 38 more locations